Tel Aviv-headquartered Fairtility, a transparent AI innovator powering in vitro fertilisation (IVF) for improved outcomes, has announced the completion of a $15 million Series A funding. This round brings the total funding to $18.5 million.
The financing round was led by Boston-based Gurnet Point Capital and saw participation from Nacre Capital and additional investors.
Focuses on advancements
Fairtility will use the investment for advanced clinical research with fertility clinics and marquee academic institutions globally, and in regulatory approval processes. The company continues to develop CHLOE beyond embryo assessment to span the full breadth of IVF treatment.
“Despite advancements in fertility treatments, IVF still only averages a 30 percent success rate per treatment cycle,” said Eran Eshed, Co-Founder and CEO of Fairtility. “We are excited to partner with such prominent investors that are helping us realize our vision of enhancing IVF outcomes and efficiency through digitization. We believe that the transparency and user-centricity of our platform will significantly improve workflow efficiency, and data-driven decision-making for better IVF outcomes. This will make IVF more accessible to a larger population of people contending with infertility.”
“We are truly excited to partner with Fairtility as they connect state of the art technology to improve women’s health and provide better infertility care for those desiring a family,” said Sophie Kornowski, Senior partner at Gurnet Point Capital. “After a long and thorough diligence process, we believe that Fairtility has the best in technology and ability to execute on our shared vision.”
“IVF is a field of medicine that is primed for AI adoption, yet current solutions remain limited in their scope. IVF professionals are not given access to data that explains AI outputs; clinicians today are asked to ‘trust’ the system,” said Howard Morgan, Chairman of Nacre Capital. “Fairtility’s approach is above the rest technologically with all the ingredients needed to create profound transformation in this market – world class data-scientists, fertility specialists and no less important, an experienced leadership team which has built numerous successful companies.”
AI in IVF procedure
Currently, IVF yields suboptimal and inconsistent outcomes due to the lack of objective and consistent methods for consolidating and interpreting end-to-end data from the embryology lab. Yet, reproductive health professionals have been slow to adopt AI technologies more commonly used in other areas of healthcare, due in part to the lack of transparency in AI analysis.
Fairtility, founded by Eran Eshed and Italy Erlich, harnesses the power of cutting-edge AI and big-data to revolutionise the outcomes of In-Vitro Fertilization (IVF).
CHLOE EQ: What does it do?
It makes AI-decision-making in IVF into a transparent process for both clinicians and patients with CHLOE EQ (Cultivating Human Life through Optimal Embryos), its Embryo Quality Assessment Assistant.
CHLOE EQ provides visibility into the biological data that informs the system’s embryo assessment conclusions. CHLOE EQ’s data output is intended to support IVF professionals’ experience and intuition, augmenting decision-making with the collective analysis of millions of data points collected from a diverse set of embryology labs and workflows globally.
Powering IVF professionals with this data facilitates improved decision-making and informative conversations with patients with the goal of reducing the number of IVF cycles to live birth and improving patient care.
